Aegis Capital Starts Marrone Bio Innovations (MBII) at Buy

Aegis Capital analyst Nathan Weinstein initiates coverage on Marrone Bio Innovations (NASDAQ: MBII) with a Buy rating and a price target of $2.00.

The analyst comments "Marrone Bio has recently generated attractive sales growth and gross margin expansion which, in combination with a management team who we feel is focused on achieving profitability, sets the company up to be an interesting investment opportunity in bio-pesticides, a niche within the agriculture market that is differentiated from chemical pesticide companies via its focus on a natural, organic, and non-chemical approach to protecting crops and increasing yields."

For an analyst ratings summary and ratings history on Marrone Bio Innovations click here. For more ratings news on Marrone Bio Innovations click here.

Shares of Marrone Bio Innovations closed at $1.37 yesterday.

You May Also Be Interested In

• Craig-Hallum Assumes DiaMedica Therapeutics Inc. (DMAC) at Buy
• Ultragenyx Pharma (RARE) PT Raised to $61 at TD Cowen
• GE Aerospace (GE) PT Raised to $180 at BofA Securities